Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR) by Godier, Anne et al.
HAL Id: hal-02342074
https://hal.archives-ouvertes.fr/hal-02342074
Submitted on 25 Feb 2020
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Management of antiplatelet therapy in patients
undergoing elective invasive procedures: Proposals from
the French Working Group on perioperative hemostasis
(GIHP) and the French Study Group on thrombosis and
hemostasis (GFHT). In collaboration with the French
Society for Anesthesia and Intensive Care (SFAR)
Anne Godier, Pierre Fontana, Serge Motte, Annick Steib, Fanny Bonhomme,
Sylvie Schlumberger, Thomas Lecompte, Nadia Rosencher, Sophie Susen,
André Vincentelli, et al.
To cite this version:
Anne Godier, Pierre Fontana, Serge Motte, Annick Steib, Fanny Bonhomme, et al.. Management of
antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French
Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis
and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care
(SFAR). Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2018, 111 (3),
pp.210–223. ￿10.1016/j.acvd.2017.12.004￿. ￿hal-02342074￿
Anaesth Crit Care Pain Med 37 (2018) 379–389Guidelines
Management of antiplatelet therapy in patients undergoing elective
invasive procedures. Proposals from the French Working Group on
perioperative haemostasis (GIHP) and the French Study Group on
thrombosis and haemostasis (GFHT). In collaboration with the French
Society for Anaesthesia and Intensive Care Medicine (SFAR)
Anne Godier a,*, Pierre Fontana b, Serge Motte c, Annick Steib d, Fanny Bonhomme e,
Sylvie Schlumberger f, Thomas Lecompte g, Nadia Rosencher h, Sophie Susen i,
Andre´ Vincentelli j, Yves Gruel k, Pierre Albaladejo l, Jean-Philippe Collet m, members of the
French Working Group on perioperative haemostasis (GIHP), P. Albaladejo n, S. Belisle o,
N. Blais p, F. Bonhommeq, A. Borel-Derlon r, J.Y. Borg s, J.-L. Bosson t, A. Cohen u, J.-P. Collet u,
E. de Maistre v, D. Faraoni w, P. Fontana x, D. Garrigue Huet y, A. Godier z, Y. Gruel aa, J. Guay o,
J.F. Hardy o, Y. Huet u, B. Ickx ab, S. Laporte ac, D. Lasne ad, J.H. Levy ae, J. Llau af, G. Le Gal ag,
T. Lecompte ah, S. Lessire ai, D. Longrois z, S. Madi-Jebara aj, E. Marret z, J.L. Mas ak,
M. Mazighi ak, P. Mismetti al, P.E. Morange am, S. Motte an, F. Mullier ao, N. Nathan ap,
P. Nguyen aq, Y. Ozier ar, G. Pernod t, N. Rosencher z, S. Roullet as, P.M. Roy at, C.M. Samama z,
S. Schlumberger au, J.F. Schved av, P. Sie´ aw, A. Steib ax, S. Susen ay,
E. van Belle az, P. van Der Linden ab, A. Vincentelli ba, P. Zufferey bb
aDepartment of Anaesthesiology and Intensive Care, Fondation Rothschild, and Inserm UMR-S1140, Paris Descartes university, 75006 Paris, France
bDivision of angiology and haemostasis and Geneva Platelet Group, University hospitals of Geneva, 1205 Geneva, Switzerland
cDepartment of Vascular Diseases, Erasme University Hospital, Universite´ Libre de Bruxelles, 1050 Brussels, Belgium
dDepartment of Anaesthesiology and Intensive Care, NHC, University Hospital-Federation de Medecine Translationnelle, 67000 Strasbourg, France
eDepartment of Anaesthesiology, Pharmacology, and Intensive Care, Geneva University Hospitals, 1205 Geneva, Switzerland
fDepartment of Anaesthesiology, Foch Hospital, 92150 Suresnes, France
gGeneva Platelet Group (GpG), Department of Medical Specialties, Faculty of Medicine, Geneva University Hospitals, University of Geneva, 1205 Geneva,
Switzerland
hCochin Hospital, Paris Descartes University, AP–HP, 75014 Paris, France
iU1011 – EGID, Inserm, Institute of haematology-transfusion, universite´ de Lille, CHU de Lille, 59000 Lille, France
jDepartment of cardiac surgery, Centre hospitalier re´gional universitaire de Lille, Lille, France
kDepartment of Haematology-Haemostasis, University-Hospital of Tours, 37044 Tours cedex, France
lDepartment of Anaesthesiology and Critical Care, Grenoble-Alpes University Hospital, Grenoble, ThEMAS, TIMC, UMR CNRS 5525, Universite´ Grenoble-Alpes,
38700 Grenoble, France
mACTION Study Group, Inserm UMR_S 1166, department of cardiology, institut de cardiologie, Pitie´-Salpeˆtrie`re Hospital, Sorbonne Universite´s_Univ Paris 06
(UPMC), AP–HP, 75013 Paris, France
nAnesthe´sie-re´animation, Grenoble, France
oAnesthe´sie, Montre´al, Canada
pHe´matologie-he´mostase, Montre´al, Canada
qAnesthe´sie-re´animation, Gene`ve, Switzerland
rHe´matologie-he´mostase, Caen, France
sHe´mostase, Rouen, France
tMe´decine vasculaire, Grenoble, France
uCardiologie, Paris, France
vHe´matologie, Dijon, France
wAnesthe´sie-re´animation, Toronto, Canada
xHe´mostase, Gene`ve, Switzerland
yAnesthe´sie-re´animation, Lille, France
zAnesthe´sie-re´animation, Paris, France* Corresponding author.
E-mail address: agodier@fo-rothschild.fr (A. Godier).
https://doi.org/10.1016/j.accpm.2017.12.012
2352-5568/C 2018 The Authors. Published by Elsevier Masson SAS on behalf of Socie´te´ franc¸aise d’anesthe´sie et de re´animation (Sfar). This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
A. Godier et al. / Anaesth Crit Care Pain Med 37 (2018) 379–389380aaHe´matologie, Tours, France
abAnesthe´sie-re´animation, Bruxelles, Belgium
ac Pharmacologie, Saint-E´tienne, France
adHe´matologie, Paris, France
aeAnesthe´sie-re´animation, Durham, USA
afAnesthe´sie, Valence, Spain
agMe´decine vasculaire, Ottawa, Canada
ahHe´matologie, Gene`ve, Switzerland
aiAnesthe´sie, Namur, Belgium
ajAnesthe´sie, Beyrouth, Lebanon
akNeurologie, Paris, France
al Pharmacologie clinique, Saint-E´tienne, France
amHe´matologie, Marseille, France
an Pathologie vasculaire, Bruxelles, Belgium
aoHe´matologie, Namur, Belgium
apAnesthe´sie-re´animation, Limoges, France
aqHe´matologie, Reims, France
arAnesthe´sie-re´animation, Brest, France
asAnesthe´sie re´animation, Bordeaux, France
atMe´decine d’urgence, Angers, France
auAnesthe´sie-re´animation, Suresnes, France
avHe´matologie, Montpellier, France
awHe´matologie, Toulouse, France
axAnesthe´sie-re´animation, Strasbourg, France
ayHe´matologie Transfusion, Lille, France
az Cardiologie, Lille, France
ba Chirurgie cardiaque, Lille, France
bbAnesthe´sie-re´animation, Saint-E´tienne, France
A R T I C L E I N F O
Article history:
Received 19 December 2017
Received in revised form 28 December 2017
Accepted 28 December 2017
Available online 5 January 2018
Keywords:
Antiplatelet agents
Surgery
Bleeding
Thrombosis
Regional anaesthesia
A B S T R A C T
The French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on
Haemostasis and Thrombosis (GFHT) in collaboration with the French Society for Anaesthesia and
Intensive Care Medicine (SFAR) drafted up-to-date proposals for the management of antiplatelet therapy
in patients undergoing elective invasive procedures. The proposals were discussed and validated by a
vote; all proposals but one could be assigned with a high strength. The management of antiplatelet
therapy is based on their indication and the procedure. The risk of bleeding related to the procedure can
be divided into high, moderate and low categories depending on the possibility of performing the
procedure in patients receiving antiplatelet agents (none, monotherapy and dual antiplatelet therapy
respectively). If discontinuation of antiplatelet therapy is indicated before the procedure, a last intake of
aspirin, clopidogrel, ticagrelor and prasugrel 3, 5, 5 and 7 days before surgery respectively is proposed.
The thrombotic risk associated with discontinuation should be assessed according to each specific
indication of antiplatelet therapy and is higher for patients receiving dual therapy for coronary artery
disease (with further refinements based on a few well-accepted items) than for those receiving
monotherapy for cardiovascular prevention, for secondary stroke prevention or for lower extremity
arterial disease. These proposals also address the issue of the potential role of platelet functional tests
and consider management of antiplatelet therapy for regional anaesthesia, including central neuraxial
anaesthesia and peripheral nerve blocks, and for coronary artery surgery.
C 2018 The Authors. Published by Elsevier Masson SAS on behalf of Socie´te´ franc¸aise d’anesthe´sie et de
re´animation (Sfar). This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
Antiplatelet agents (APAs) are prescribed to prevent arterial
thrombosis and especially the recurrence of thrombotic events.
The four main oral APAs have two distinct pharmacological
targets: aspirin inhibits the enzyme cyclooxygenase 1 and
therefore thromboxane A2 synthesis, while clopidogrel, prasugrel
and ticagrelor inhibit the adenosine diphosphate (ADP) pathway
via the platelet receptor P2Y12.
Many patients receiving long-term antiplatelet therapy will at
some time require an elective invasive procedure. This setting
requires specific management of antiplatelet therapy. The
discontinuation of antiplatelet therapy to perform an invasive
procedure increases the risk of thrombotic events while the
continuation increases the bleeding risk during the procedure.These two risks must be assessed sequentially to determine the
optimal management for the planned invasive procedure, and to
choose between continuation, discontinuation or modification of
antiplatelet therapy, or postponement of the procedure.
The perioperative management of antiplatelet therapy has been
the subject of a few national and international guidelines, but they
are piecemeal or old, and do not take recent work into account [1–
3]. The French Working Group on Perioperative Haemostasis
(GIHP) and the French Study Group on Haemostasis and
Thrombosis (GFHT) have been working together to draft up-to-
date proposals for the management of antiplatelet therapy in
patients undergoing elective invasive procedures.
The methodology for establishing these proposals was as
follows. The different parts of this text were assigned to five
working groups, consisting of members of the GIHP or the GFHT.
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literature. The other groups then re-read, discussed and modified
these proposals, which were then subjected to critical analysis by
all GIHP and GFHT members. Finally, these proposals were
validated by a vote (37 voters), thereby determining the strength
of each of the proposals, as follows. To make a proposal on an item,
at least 50% of the members had to express their agreement (for an
agreement to be strong, the threshold was set at 70%), while
disagreement was when fewer than 20% of them agreed. In the
absence of agreement, the proposals were reformulated and voted
upon again to achieve a better consensus. The proposals were
made in collaboration with the French Society for Anaesthesia and
Intensive Care Medicine (SFAR).
2. Bleeding risk due to continuation of antiplatelet therapy
during an invasive procedure
Continuing antiplatelet therapy in the periprocedural period is
likely to increase the risk of bleeding intra- and postoperatively
depending on the invasive procedure and the type of APA. The
main issue is to determine the situations where the increased
bleeding risk is not acceptable, thereby needing perioperative
changes in antiplatelet therapy. Studies evaluating the risk of
bleeding associated with the perioperative continuation of one or
more APAs have methodological drawbacks. Nevertheless, as a
general rule, the bleeding risk due to clopidogrel is lower than that
with the new P2Y12 receptor inhibitors, prasugrel and ticagrelor,
and is greater with dual therapy (aspirin + P2Y12 inhibitor) than
with monotherapy (most often aspirin). The aspirin-induced bleeding
risk could be lower than that with clopidogrel, since thromboxane A2
plays a lesser role in platelet activation than ADP [4].
The risk of bleeding due to antiplatelet therapy varies from one
invasive procedure to another and includes not only the volume of
bleeding and transfusion requirement but also the onset of a
haematoma in the event of functional surgery or the need for
surgical revision. The risk of bleeding during invasive procedures is
usually classified pragmatically, depending on the possibility of
performing the procedure in APA-treated patients [5–11]. Several
classifications have been proposed by various scientific societies
and globally by the ‘‘Stent after Surgery’’ group [12]. These
classifications may vary depending on the surgical teams and
patients considered.
Proposals
 The risk of bleeding related to the invasive procedure
can be divided into high, moderate and low risk (strong
agreement).
 Procedures carrying a high risk of bleeding are defined
as not feasible in patients on antiplatelet therapy, even
aspirin monotherapy. For such procedures, the aspirin-
induced bleeding risk is either unknown but considered
as potentially worrying, or unacceptable or deemed as
such, with a lethal or functional risk. They are infrequent
and include certain procedures in urology when alterna-
tive techniques cannot be used, numerous procedures in
intracranial neurosurgery, surgery with major tissue
resection or wide dissections, and certain procedures of
liver or thoracic surgery (strong agreement).
 Procedures carrying a moderate risk of bleeding are
defined as feasible in patients on aspirin alone. This is
the case with majority of invasive procedures (strong
agreement). Procedures carrying a low risk of bleeding are defined as
feasible in patients on dual antiplatelet therapy. They
include cataract surgery, most dental procedures,
certain urologic procedures such as urethrocystoscopy,
certain vascular surgery procedures, certain bronchos-
copies, certain gastrointestinal endoscopy procedures
including all diagnostic endoscopies with or without
biopsies, endoscopic retrograde cholangiopancreatogra-
phy without sphincterotomy, and colonic polypecto-
mies < 1 cm. However, experience with ticagrelor or
prasugrel is limited. In addition, the co-administration
of other drugs interfering with haemostasis or the
presence of comorbidities increasing the risk of bleeding
may necessitate the discontinuation of the P2Y12
inhibitor (strong agreement).
 When there is no consensus or standard to classify a
procedure in one of these categories, it is proposed that a
referent team (surgeon, anaesthetist, cardiologist, pul-
monologist, vascular specialist or specialist in haemos-
tasis) in the hospital defines a care plan on a case-by-
case basis or for a given profile of patient or procedure.
Such decisions are to be recorded in the patient’s file or
in the hospital’s procedures (strong agreement).
 Regarding gastrointestinal endoscopies, it is proposed
that management strategies for antiplatelet therapy be
defined in each hospital according to the profile of the
patients and therefore the invasive procedure that may
be potentially performed during the endoscopy. Thus, if
the probability of an invasive procedure requiring
discontinuation of antiplatelet therapy for a given
patient profile is considered high, the appropriate
strategy is adopted (e.g. sphincterotomy, gastrostomy).
On the other hand, if the probability is low, the
antiplatelet therapy is continued (e.g. chronic inflam-
matory diseases of the intestine, dyspepsia). When the
probability and the nature of the lesions to be resected is
not known a priori, each hospital decides on its policy
(e.g. endoscopy for polyp detection) (strong agreement).
3. Duration of APA discontinuation and substitutes
The optimal duration of discontinuation of an APA before an
invasive procedure is the shortest duration that can reduce the
excess risk of bleeding associated with it. It depends on the
pharmacokinetic and pharmacodynamic characteristics of the APA
and on published clinical studies evaluating APA-related bleeding
based on their duration of discontinuation for various invasive
procedures, including surgeries that may be considered as models,
especially cardiac surgery, but also total hip or knee replacement,
hip fracture surgery, etc.
The basic points to be considered for determining the duration
of a possible discontinuation of an APA, if deemed necessary, are as
follows:
 the main platelet functions involved in haemostasis are
adhesion to the sub-endothelium, aggregation, secretion, and
procoagulant activities. They variably depend on the self-
amplification systems of activation supported by thromboxane
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laboratory or at the bedside remains imperfect;
 the basic effect of an APA is the inhibition of its target: aspirin
irreversibly inhibits the enzyme cyclooxygenase 1 and thus the
synthesis of thromboxane A2, while the P2Y12 inhibitors,
clopidogrel, prasugrel and ticagrelor, inhibit the P2Y12 platelet
receptor for ADP;
 full recovery of the target’s functioning is not required for the
complete recovery of the platelet functions that depend on it;
 complete recovery of platelet functions dependent on throm-
boxane A2 or ADP is not always necessary to achieve the
sufficient haemostatic competence required for a safe invasive
procedure;
 recovery of the target’s functionality varies from one patient to
another; but there is a well-established time interval after which
recovery is achieved in all patients;
 no haemostatic safety threshold guaranteeing the absence of the
perioperative risk of bleeding related to any residual effects of
APA treatment has been established, whatever the platelet
function test used, be it in the laboratory or at the bedside;
 standardised and anticipated durations of APA discontinuation
are more convenient than decisions taken on a day-to-day basis
after functional testing for elective procedure scheduling.
The differences between APAs in the duration of discontinua-
tion are explained by a combination of factors: thromboxane A2
plays a lesser role in platelet activation than ADP; thromboxane A2
produced by the fraction of naive platelets can stimulate all
platelets in the vicinity, whether or not their cyclooxygenase
1 enzymes are inhibited; the level of inhibition before discontinu-
ation, which classifies P2Y12 inhibitors according to their potency
(prasugrel and ticagrelor being more potent than clopidogrel); for
ticagrelor, the reversibility of its inhibitory effect.
For the three APAs with an irreversible effect, i.e. aspirin,
clopidogrel and prasugrel, recovery after discontinuation
depends on the turnover of circulating platelets, senescent
inhibited platelets being removed from the circulation and
replaced by newly produced platelets, unexposed to the drug
(‘‘naı¨ve’’). Finally, in the absence of a loading dose, the full
inhibitory effect that the APAs can induce in a patient takes
several days to be obtained.
3.1. Aspirin
The French Haute Autorite´ de la sante´ (HAS) recommends that
aspirin should not be given for three days before the procedure
[2]. However, this recommended duration may be adjusted.
Aspirin inhibits the synthesis of thromboxane A2 irreversibly.
The time required for the full recovery of thromboxane A2
synthesis is that of the total turnover of circulating platelets, i.e.
platelet lifetime, which is normally about 10 days but may in some
circumstances be shorter. However, recovery does not need to be
total for the complete correction of the platelet functions that
depend on thromboxane A2 synthesis [13–15], nor for haemostatic
competence to be sufficient to safely undergo an invasive
procedure. Interindividual variability in correction of platelet
function explains why not all subjects have complete correction
after four days [16]. The association between results of platelet
function tests and bleeding risk is not straightforward. For
instance, in a randomised trial investigating six durations of
aspirin discontinuation, from 0 to five days, in 258 patients treated
with 100 mg aspirin and requiring tooth extraction [15], (also with
212 patients not taking aspirin), the effects of aspirin on platelet
aggregation induced by arachidonic acid assessed with the
Multiplate1 disappeared 96 hours after aspirin withdrawal.
However, the incidence of haemorrhagic complications wascomparable regardless of the duration of discontinuation, includ-
ing < 96 hours. Finally, faster recovery of aspirin-inhibited platelet
function may occur in some patients, e.g. due to accelerated
platelet turnover, such as diabetics, patients with high weight [17]
and those with thrombocytosis in a setting of myeloproliferative
neoplasia.
The haemostatic safety threshold guaranteeing the absence of
perioperative risk of bleeding associated with aspirin treatment
has not been established. Moreover, the functional platelet tests
used in studies addressing this issue have yielded inconsistent
results [18]. The data is therefore too preliminary to use those tests
in clinical practice for the management of aspirin before an elective
invasive procedure.
In conclusion, a three-day washout of aspirin leads to an
improvement in platelet functions that is often but not always
sufficient for full correction of platelet functions. However, for
procedures with a high risk of bleeding, i.e. the only procedures for
which discontinuation of aspirin is essential, the goal is to
completely correct the platelet functions inhibited by aspirin.
This must be achieved in all patients undergoing these procedures.
It is therefore proposed that invasive procedures carrying a high
risk of bleeding such as neurosurgery should be performed only
after five days of aspirin washout.
Although in most patients the maximal effect on platelets is
achieved with 75 mg o.d., for various reasons a higher dose may be
given. Since the bleeding risk is not greater with 300 than 75–100
(but for gastrointestinal bleeding), there is no reason to change the
chosen regimen perioperatively.
3.2. P2Y12 inhibitors
The HAS recommends that clopidogrel, prasugrel and ticagrelor
should not be given for five, seven and five days before the
procedure, respectively [2]. The ESC/ESA recommendations are
comparable [1].
3.3. Usefulness of platelet functional tests to adjust the duration of
P2Y12 inhibitor washout before an invasive procedure
Given the variability of platelet response to P2Y12 inhibitors in
terms of both intensity and changes over time, the suggestion to
guide duration of their discontinuation according to the results of a
platelet functional test is attractive [19]. However, while there is a
consensus on the existence of a relationship between the level of
the impairment of platelet functions and the risk of spontaneous
haemorrhage after insertion of an endovascular prosthesis [20],
the relationship between this level and the associated periopera-
tive risk of bleeding have received little attention. Several tests
may be used to evaluate platelet functions while on antiplatelet
therapy with a P2Y12 inhibitor, but sometimes inconsistent results
have been found [21,22]. Moreover, definitions of perioperative
bleeding events widely differ. Nevertheless, studies to date tend to
show that the intensity of inhibition of platelet functions that
depend on ADP is associated with an increased risk of perioperative
bleeding. A meta-analysis showed that late discontinuation of
P2Y12 inhibitors was associated with an increased risk of death and
reoperations due to bleeding compared to earlier discontinuation
in patients undergoing coronary artery surgery [23]. Patients
allocated to prasugrel treatment in the TRITON-TIMI 38 study and
requiring coronary artery surgery had a four-fold greater risk of
major bleeding than those treated with clopidogrel [24]. Further-
more, patients who had taken ticagrelor in the 24 hours before
coronary artery surgery tended to have larger chest tube drainage
than those treated with clopidogrel in the PLATO study [25].
It has therefore been proposed that evaluation of platelet
function might improve the prediction of the perioperative
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type of P2Y12 inhibitor, such as clopidogrel [26]. An early study
used TEG1 Platelet Mapping for clopidogrel-treated patients
undergoing coronary artery surgery. It showed that being in the
higher tertile of platelet function inhibition measured with this
test was the only factor independently associated with increased
blood loss and transfusion requirement [26]. Another study
showed that a strategy based on preoperative testing of platelet
functions with the same test (TEG1 Platelet Mapping) to
determine the timing of CABG in clopidogrel-treated patients
was associated with the same amount of bleeding as that observed
in clopidogrel-naive patients and a 50% shorter waiting time than
the standard five days [27].
Emerging evidence based on functional platelet testing
challenges the five-day duration of ticagrelor discontinuation
before surgery that carries a high bleeding risk. A Swedish cardiac
surgery registry compared perioperative bleeding in the setting of
emergency or semi-emergency coronary artery surgery in patients
treated with dual antiplatelet therapy consisting of aspirin and
clopidogrel (n = 978) or ticagrelor (n = 1266) [28]. The incidence of
major bleeding was high when ticagrelor or clopidogrel were
discontinued less than 24 hours before surgery. In the ticagrelor
group, there was no significant difference between discontinuation
72–120 hours or more than 120 hours before surgery, as opposed
to what was observed in the clopidogrel group. The overall
incidence of major bleeding complications was lower with
ticagrelor than with clopidogrel.
An analysis of a Dutch registry also showed that a three-day
washout of ticagrelor could be considered [29]. Between 2012 and
2014, 626 APA-treated patients underwent coronary artery
surgery with cardiopulmonary bypass, including 222 with dual
antiplatelet therapy. They were stratified according to the
duration of discontinuation of the P2Y12 inhibitor before surgery:
ticagrelor discontinued  72 hours before surgery (Group Ti  72,
n = 61); ticagrelor discontinued 72 to 120 hours before surgery
(Group Ti 72–120, n = 23); clopidogrel discontinued  120 hours
(Clo group  120, n = 125) or between 120–168 hours before
surgery (Group Clo 120–168, n = 13). The standard duration of
discontinuation of P2Y12 inhibitors in the center before scheduled
surgery was 120 hours. Transfusion requirements were higher in
the Ti group  72 and the Clo group  120 than in the aspirin-
alone group, (72.1% and 71.2% respectively vs. 41.3%, P < 0.001 for
both comparisons), but surgical re-exploration rates were not
different. Multivariate analysis comparing the Clo groups  120,
C 120–168, Ti  72 and Ti 72–120 with the aspirin-alone group
revealed Clo group  120 and Ti group  72 as predictors of
bleeding-related complications. No increased incidence in
bleeding-related complications was seen when ticagrelor was
discontinued > 72 hours or clopidogrel > 120 hours prior to
surgery. Although these data relate to cardiac surgery, they
could probably be extrapolated to non-cardiac invasive pro-
cedures since the correction of platelet functions does not depend
on the procedure.
However, the correction of platelet functions that depend on
ADP 72 to 120 hours after discontinuing ticagrelor showed
significant interindividual variability. ADP-induced aggregation
was assessed with the Multiplate1 after ticagrelor discontinuation
in 25 patients undergoing urgent coronary artery surgery
[30]. While most patients had recovered a platelet response
deemed sufficient after 72 hours of discontinuation (threshold at
22 aggregation units), 25% of patients remained below this
threshold. However, in another prospective study that also
included patients treated with ticagrelor and requiring cardiac
surgery, preoperative ADP-induced platelet aggregation assessed
by Multiplate1 predicted the risk for severe bleeding complica-
tions [31]. Importantly, more patients with ADP-inducedaggregation below the 22-unit threshold developed severe
bleeding than those above (61% vs. 14%, P < 0.001).
Altogether, these data suggest that a 72-to-120-hour ticagrelor
discontinuation is sufficient for most patients. However, within
this window, the correction of platelet functions inhibited by
ticagrelor is variable from one patient to another. Platelet inhibition
persists in about one quarter of patients after a 72-hour
discontinuation and is associated with the risk of perioperative
bleeding. It is therefore proposed that invasive procedures should be
performed only after five days of ticagrelor discontinuation.
Based on these data, both the European Societies of Cardiovas-
cular and Cardio-Thoracic Surgery and the Society of Thoracic
Surgeons used to recommend assessing the level of inhibition of
platelet functions to determine the interval between the last intake
of P2Y12 inhibitors and the invasive procedure [11,32]. However,
studies supporting these recommendations are few and underpow-
ered to accurately assess bleeding events, and involved patients
treated with clopidogrel or ticagrelor and not those treated with
prasugrel. Therefore, the most appropriate assessment of platelet
function remains debated. Finally, the type of surgery studied in this
context is almost always coronary artery surgery, and the safety of
the determination of the optimal duration of P2Y12 inhibitor
discontinuation based on a laboratory test before another type of
intervention such as neurosurgery is not established. Thus, it seems
premature to recommend the routine use of such an attitude, which
is no longer proposed in the recent guidelines of the European
Society of Cardiology [1]. Available data suggest at most the use of a
platelet functional test to reduce the duration of discontinuation of
P2Y12 inhibitors in urgent coronary artery surgery.
Proposals
 If discontinuation of antiplatelet therapy is indicated
before an invasive procedure, it should be as follows
(strong agreement):
 last intake of aspirin on D-3 (D0 corresponds to day
of procedure)*,
 last intake of clopidogrel and ticagrelor on D-5***,
 last intake of prasugrel on D-7*,
 (*) For intracranial neurosurgery:
 last intake of aspirin on D-5,
 last intake of clopidogrel and ticagrelor on D-7,
 last intake of prasugrel on D-9 (strong agreement);
 (**) Recent data suggest that urgent coronary artery
surgery can be performed after a shorter ticagrelor
discontinuation, of three to five days, with no excess risk
of bleeding in most patients. However, in this setting,
patients without recovery deemed sufficient of ticagrelor-
induced platelet inhibition are at increased risk of bleeding.
 It is recommended not to bridge antiplatelet agents either
heparin (UFH or LMWH) or NSAIDs (strong agreement).
 In patients treated with aspirin at doses up to 300 mg/
day in the long-term, it is proposed not to reduce the
dosage for surgery (strong agreement).
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elective invasive procedure
The discontinuation of long-term antiplatelet therapy is
associated with the occurrence of cardio-neurovascular events,
the frequency of which varies with the indication for antiplatelet
therapy [8,33]. The thrombotic risk associated with discontinuing
treatment should therefore be assessed according to each of its
indications.
4.1. APA monotherapy
4.1.1. Cardiovascular prevention
The perioperative effect of aspirin prescribed for primary or
secondary cardiovascular prevention has been evaluated only in a
few randomised trials in non-cardiac surgery. The PEP trial
compared preoperative 160 mg aspirin continued for 35 days
with placebo in 13,356 patients undergoing surgery for hip
fracture [34]. Aspirin increased bleeding, RBC transfusion was
more frequent and larger, and there was more digestive bleeding.
In addition, although it reduced venous thromboembolic events,
aspirin did not reduce the incidence of myocardial infarction or
stroke.
The POISE-2 trial evaluated the benefit of aspirin versus placebo
in 10,010 patients undergoing non-cardiac surgery [35]. Patients
were stratified according to whether they were treated with long-
term aspirin before surgery. Aspirin did not decrease the composite
endpoint of myocardial infarction and mortality but increased the
risk of major bleeding. The authors concluded that the risk
of continuing aspirin perioperatively was greater than the risk of
discontinuing it. However, fewer than 1/3 of the included patients
had a cerebrovascular or cardiovascular history. In addition,
patients with recent stents and those scheduled for carotid surgery
were excluded, since it is recommended to continue aspirin for
carotid endarterectomy [36]. At most, POISE-2 suggests that
aspirin has no perioperative benefit for patients with low
cardiovascular risk. No conclusion can be drawn for high-risk
patients.
The STRATAGEM trial compared placebo to aspirin prescribed
for secondary prevention (coronary artery disease, ischaemic
stroke or transient ischaemic attack, peripheral arterial disease) in
291 patients undergoing intermediate- or high-risk non-cardiac
surgery [37]. For 41% of them, there was a history of acute coronary
syndrome. The trial, which was interrupted prematurely for
inclusion difficulties, showed no difference in the occurrence of
major thrombotic or haemorrhagic events.
Finally, the ASINC trial compared aspirin with placebo in
patients with cardiac risk factors undergoing elective, high- or
intermediate-risk non-cardiac surgery [38]. More than 2/3 of
patients had coronary artery disease and 1/5 had cerebrovascular
disease. The trial showed that aspirin reduced major cardiac events
by 80% compared with placebo. There was no excess risk of
bleeding but the trial was unpowered due to its premature
termination.
4.1.2. History of ischaemic stroke
For patients receiving antiplatelet therapy for secondary stroke
prevention, published data, which are scarce, suggest that its
discontinuation is associated with the occurrence of thrombotic
events. Thus, the risk of recurrent ischaemic stroke or major
cardiovascular events following APA discontinuation was investi-
gated during the follow-up of PRoFESS, a randomised, double-
blind, factorial study that included 20,332 patients with recent
ischaemic stroke (4 months prior to inclusion) [39]. The aim of the
trial was to evaluate the efficacy of the combination of extended-
release dipyridamole with aspirin versus clopidogrel monotherapyand the efficacy of telmisartan versus placebo [40]. The secondary
analysis of the trial showed that patients who discontinued
antiplatelet therapy for any reason had an absolute risk increase in
stroke recurrence or a cardiovascular event of 2.02% and 1.83%
within 30 days of discontinuation of dipyridamole/aspirin and
clopidogrel, respectively, compared to patients who continued
treatment [39]. These results may have been biased because the
authors did not perform a multivariate adjustment to account for
the characteristics of patients who discontinued treatment. Cohort
and case-control studies have also reported an increased risk of
recurrent stroke following discontinuation of antiplatelet therapy
[41–44].
4.1.3. Lower extremity artery disease
Patients receiving antiplatelet therapy for lower extremity
artery disease are at high risk of cardiovascular events, particularly
in the postoperative period [45,46], but the incidence of
cardiovascular events related to discontinuation in such patients
is not known. A cohort study involving 181 consecutive patients
admitted to hospital for acute lower limb ischemia showed that a
thrombotic event occurred in 11 patients (6.1%) after discontinuing
aspirin, four of whom stopped before a surgical procedure [47].
Proposals for APA monotherapy
 For patients not receiving antiplatelet therapy, aspirin
therapy should not be initiated in order to reduce the
risk of perioperative cardiovascular events before non-
cardiac surgery, with the exception of carotid endarter-
ectomy (strong agreement).
 Aspirin should be discontinued preoperatively when
prescribed for primary prevention (strong agreement).
 Aspirin should not be discontinued preoperatively when
prescribed for secondary prevention (cardiovascular
prevention, history of ischaemic stroke, lower extremity
artery disease), except for procedures with a high risk of
bleeding (strong agreement).
 For patients treated with monotherapy with a P2Y12
inhibitor and scheduled for intermediate-risk surgery,
the P2Y12 inhibitor should be replaced by aspirin with a
daily dose of 75 to 100 mg (strong agreement). This
change could be made more than seven days prior to
surgery to allow complete correction of platelet inhibi-
tion induced by P2Y12 inhibitors (strong agreement).
 Antiplatelet therapy, if discontinued, should be resumed
as soon as possible, according to the risk of postopera-
tive bleeding, in patients who have an indication for
long-term APA monotherapy (strong agreement).
4.2. Dual antiplatelet therapy for coronary artery disease
Four to 15% of patients with coronary stents require non-
cardiac surgery within one year after stent implantation [48]. The
management of those patients while still on dual antiplatelet
therapy (DAPT) involves consideration of: (1) the increased
perioperative bleeding risk, especially when DAPT is continued;
(2) the risk of stent thrombosis, especially if DAPT has to be
discontinued; and (3) the consequences of delaying the invasive
procedure [49–51]. A multidisciplinary approach involving the
anaesthetist, the interventional cardiologist, the cardiologist,
Table 1
Characteristics of high-thrombotic risk after stent implantation [1].
Chronic kidney disease (i.e. creatinine clearance < 60 mL/min)
Diffuse multivessel disease especially in diabetic patients
Prior stent thrombosis on adequate antiplatelet therapy
Stenting of the last remaining patent coronary artery
At least 3 lesions treated
At least 3 stents implanted
Bifurcation with 2 stents implanted
Total stent length > 60 mm
Treatment of a chronic total occlusion
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used to assess the risks, weigh them up and determine the best
management accordingly.
The perioperative period is a period of risk for ischaemic events.
Regardless of the continuation or discontinuation of antiplatelet
therapy, invasive procedures induce a proinflammatory and pro-
thrombotic state thereby increasing the risk of coronary thrombo-
sis at the level of the stented vascular segment as well as
throughout the coronary vasculature [52,53]. An increased risk of
ischaemic events following non-cardiac surgery has been demon-
strated with first-generation drug-eluting stents [54] but also in
the first weeks after stent implantation [55,56]. Thus, the benefit/
risk ratio of an invasive procedure programmed after stent
implantation and/or myocardial infarction should be systemati-
cally assessed in a multidisciplinary manner, especially in the case
of high-risk procedures such as malignant tumor surgery or
vascular aneurysm repair. To reduce the ischaemic risk and the risk
of bleeding and transfusion related to the continuation of
antiplatelet therapy, the invasive procedure should be postponed
when possible until the end of the recommended duration of DAPT.
Previous recommendations on the duration of APA discontinu-
ation and resumption for non-cardiac surgery [57,58] were based
on registries of patients treated with first-generation drug-eluting
stents [50,59].
Compared to first-generation drug-eluting stents or to bare
metal stents, the new-generation drug-eluting stents are more
effective and safer, with a lower risk of stent thrombosis and a
shorter minimum duration of DAPT [60–63]. In addition, the PARIS
registry has shown that DAPT discontinuation grounded on
physician judgment in patients requiring an invasive procedure
is not associated with an increased risk of ischaemic event, unlike
discontinuation for poor compliance or bleeding [64].
Most registries agree that the risk of the recurrence of the
ischaemic event reaches a stable level three to six months after
active stent implantation [8,9,42]. However, the absence of a
control group of non-operated patients exposes results to biases
related to the type or urgency of invasive procedure. This makes it
difficult to establish an optimal duration allowing an invasive
procedure with a minimal risk of an ischaemic event after stenting
or acute coronary syndrome. A North American registry circum-
vented those limitations by pairing two cohorts of stented patients,
one undergoing an invasive procedure, the other not. It confirmed
that the increased risk of cardiovascular events related to surgery is
greater during the first six months after stenting, and stabilises at
1% thereafter [65]. A Danish registry also offset those limitations by
comparing two cohorts of patients treated invasively, one with
active stent implantation in the previous 12 months (n = 4003) and
the other without known history of coronary artery disease and
undergoing the same type of procedure (n = 20,232) [48]. It
showed an increased risk of myocardial infarction and cardiac
death in the group with a previous stenting. Interestingly, this
increased risk was limited to the first month after stent
implantation, suggesting that the invasive procedure should be
postponed for at least one month, if possible, after stent
implantation.
Analysis of a registry of 26,661 US veterans undergoing non-
cardiac surgery within 24 months of stent implantation showed
that major cardiac events were more common in patients with a
stent implanted for myocardial infarction (7.5%) compared with
other indications, including unstable angina (2.7%) or revascula-
risation not associated with acute coronary syndrome (2.6%)
[66]. The risk of events was much higher when the invasive
procedure was performed within three months after stent
implantation for myocardial infarction compared to the third
group (OR: 5.25, 95% CI: 4.08–6.75). The risk decreased over time
but remained higher even 12–24 months after stenting. Theauthors proposed that invasive procedures in patients with a stent
implanted for myocardial infarction should be postponed for six
months. The same postponement was proposed for patients with
myocardial infarction without stent implantation, as well as for
patients who had stent implantation associated with a high
thrombotic risk (Table 1).
For patients whose invasive procedure cannot be deferred until
the end of the recommended duration of DAPT, the durations of
P2Y12 inhibitor discontinuation are those mentioned above. For
patients at very high risk of stent thrombosis, particularly those
requiring discontinuation of both APAs in the first month, a
bridging with a reversible intravenous APA was considered
[67]. However, for rapidly reversible anti-GPIIb-IIIa agents such
as eptifibatide and tirofiban, the meta-analysis of the eight studies
that included 280 patients concluded that there was a possible risk
of bleeding associated with a persistent risk of stent thrombosis
[68]. Cangrelor, a parenteral and reversible inhibitor of the P2Y12
receptor, is another option in the perioperative setting, with a well-
established antithrombotic effect [69] and a faster reversibility
than anti-GPIIb-IIIa agents [70]. However, none of these parenteral
APAs have marketing authorisation for this indication. The use of
concomitant parenteral anticoagulation is not recommended given
the potential increase in the risk of bleeding.
Proposals for patients on dual antiplatelet therapy
 Preoperative APA management and postoperative res-
tarting may be discussed with the patient’s cardiologist
or a referent cardiologist and traced in the patient’s file
for elective procedures carrying an intermediate or high
risk of bleeding (strong agreement).
 Non-cardiac elective procedures should be postponed
until completion of the full course of DAPT when it does
not pose a major life-threatening or functional risk to
the patient (strong agreement).
 If this postponement is not possible, non-cardiac
elective procedures should be postponed beyond the
first month following stent implantation, regardless of
the type of stent or indication (myocardial infarction or
stable coronary artery disease). If the procedure cannot
be postponed beyond the first month, it should be
undertaken in hospitals where catheterisation labora-
tories are available 24/7 (strong agreement).
 Non-cardiac elective procedures should be postponed
for up to 6 months in patients with recent myocardial
infarction or with a stent associated with a high
thrombotic risk (strong agreement).
 Aspirin should be continued perioperatively. If it has to
be discontinued, it should be resumed as early as
possible after the invasive procedure, if possible the
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bleeding (strong agreement).
 If P2Y12 inhibitors have to be discontinued periopera-
tively, they should be resumed early, if possible within
24 to 72 hours after surgery, given the increased
thrombotic risk. Resumption is performed with the
same P2Y12 inhibitor as preoperatively (strong agree-
ment). No recommendation can be made regarding the
use or not of a loading dose.
 If both APAs have to be discontinued within one month
after stent implantation, a bridging strategy with an
intravenous antiplatelet agent such as tirofiban or
cangrelor can be considered on a case-by-case basis
after multidisciplinary discussion (off-label use). In
these exceptional situations associated with a high risk
of bleeding and thrombosis, bridging must be performed
in an intensive care unit and surgery must be performed
in hospitals where catheterisation laboratories are
available 24/7 (strong agreement).
 NSAIDs should not be administered perioperatively in
patients treated with DAPT (strong agreement). Periop-
erative use of coxibs is possible.
5. Regional anaesthesia
5.1. APAs and central neuraxial anaesthesia
Spinal epidural haematoma is a very rare but potentially
catastrophic complication of central neuraxial anaesthesia (ALR-
R), which includes spinal anaesthesia and epidurals with or
without catheters [71]. Risk factors include haemostatic disorders,
traumatic punctures and female gender [3,71]. The risk is greater
for epidural anaesthesia, especially with a catheter, than for spinal
anaesthesia [3].
The risk of spinal epidural haematoma related to aspirin seems
very low. It has only been reported anecdotally after many years of
practice in a very large number of patients undergoing spinal
anaesthesia [3]. No spinal epidural haematoma attributed to
aspirin has been reported in the large studies that evaluated this
risk in orthopaedics and obstetrics. In the few case reports of spinal
haematoma involving aspirin therapy, additional complicating
factors were present, particularly injections of low molecular
weight heparin close to a neuraxial procedure or catheter ablation
[3,72].
The P2Y12 inhibitors carry a greater risk of bleeding than
aspirin. Cases of peri-medullary haematoma have been reported
with clopidogrel. Spinal anaesthesia is not advisable with these
APAs [3,71].
Proposals
 Aspirin is not a contraindication to central neuraxial
anaesthesia if the benefit–risk ratio is favourable, if
there is no associated abnormality of haemostasis,
including anticoagulant therapy. If possible, single-
puncture spinal anaesthesia is preferable to epidural
anaesthesia (strong agreement).
 Central neuraxial anaesthesia is contraindicated in
patients on P2Y12 inhibitors (clopidogrel, prasugrel,ticagrelor), unless those AAPs were discontinued re-
spectively 5, 7 and 5 days before the procedure (strong
agreement).
 The insertion of an epidural catheter can complexify
management of APAs. Catheter manipulation and remov-
al carry similar risks to insertion and the same criteria
should apply. Catheter removal follows the same rules as
those for its insertion. Use of an epidural catheter should
not compromise the postoperative resumption of APAs,
especially P2Y12 inhibitors (strong agreement).
5.2. APAs and peripheral nerve blocks
Wound haematoma is a rare complication of peripheral nerve
blocks [73]. Haematoma carries three risks: surgical revision for
evacuation, transfusion and nerve damage by compression.
Treatment with APAs, especially P2Y12 inhibitors, is a risk factor
for haematoma [3]. However, aspirin probably carries a very low
risk. The risk of haematoma is greater during deep punctures, in
the absence of compression, and when antiplatelet and anticoag-
ulant therapies are combined [3]. Ultrasound guidance reduces the
risk of vascular puncture [74].
Peripheral nerve blocks can be divided into two groups
according to the degree of bleeding risk:
 low bleeding risk peripheral blocks where, if bleeding occurs, it
is easily controllable, and the area of bleeding can be compressed
[75]. These include superficial blocks such as the femoral nerve
block, the axillary plexus block and the popliteal sciatic nerve
block. These blocks could be performed in patients on APA
treatment if the benefit/risk ratio is favourable and justified [3];
 high bleeding risk blocks where, in the event of bleeding, the
area cannot be compressed or the consequences of the bleeding
are potentially serious [75]. These include deep blocks such as
the infraclavicular brachial block, the para-sacral sciatic block,
and the posterior lumbar plexus block. These blocks are
contraindicated in patients on P2Y12 inhibitors [3]. These blocks
could be performed in patients on aspirin if the benefit/risk ratio
is favourable and justified [3].
While peribulbar anaesthesia has been performed in ophthal-
mology without any complications in large series of aspirin-
treated patients, few data are available in patients treated with
clopidogrel and even less with ticagrelor or prasugrel [76]. The risk
of bleeding with peribulbar anaesthesia is low. Nevertheless, if
bleeding occurs, compression is not possible. While the SFAR and
the French Society of Ophthalmology recommend performing
peribulbar anaesthesia with a single puncture in patients treated
with a direct oral anticoagulant, they have not adopted a position
for patients treated with P2Y12 inhibitors (http://attitude.sfo.asso.
fr/professionnels). Topical or sub-tenonial anaesthesia may be
preferred if they are sufficient.
Proposals
 Peripheral nerve blocks with low risk of bleeding could
be performed in patients on mono or dual antiplatelet
therapy according to the benefit/risk ratio. Those blocks
include superficial blocks such as the femoral block,
axillary block, popliteal sciatic block, etc. (strong
agreement).
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could be performed in patients on aspirin monotherapy
if the benefit/risk ratio is favourable. These blocks are
contraindicated in patients on P2Y12 inhibitors (clopi-
dogrel, prasugrel, ticagrelor), unless they were discon-
tinued respectively 5, 7 and 5 days before the procedure.
These blocks include deep blocks such as the infrac-
lavicular block, para-sacral sciatic block, posterior
lumbar plexus block, etc. (strong agreement).
 Those blocks (superficial or deep) should be performed
using ultrasound guidance by an operator with experi-
ence in the technique (strong agreement).
 The insertion of a perineural catheter should not
compromise the postoperative resumption of APAs,
especially P2Y12 inhibitors. Catheter removal follows
the same rules as catheter insertion (strong agreement).
6. Coronary artery surgery
Most patients requiring coronary revascularisation by coronary
artery surgery are treated with one or two APAs. It is important to
assess the risk of cardiovascular complications at preoperative
discontinuation of these treatments and to determine whether this
risk is greater than the risk of bleeding associated with their
continuation during surgical revascularisation, especially in the
event of cardiopulmonary bypass.
6.1. Management of aspirin for coronary artery surgery
The aim of continued perioperative administration of aspirin is
to reduce the likelihood of perioperative cardiovascular events. A
meta-analysis of 13 randomised trials (n = 2399 patients) involv-
ing patients undergoing coronary artery surgery assigned to
preoperative aspirin therapy or no aspirin/placebo concluded that
aspirin reduces perioperative myocardial infarction without
reducing mortality, but at the cost of increased bleeding, blood
transfusion, and surgical re-exploration [77]. The ATACAS ran-
domised trial, with 2100 patients undergoing coronary artery
surgery, concluded differently as the administration of preopera-
tive aspirin resulted in neither a lower risk of death or thrombotic
complications nor a higher risk of bleeding, including reoperation
for haemorrhage, than that with placebo [78]. Finally, as in non-
cardiac surgery, low molecular weight heparins should not be used
for aspirin bridging. They promote bleeding, are difficult to
antagonise and are less effective [79].
6.2. Management of P2Y12 inhibitors for coronary artery surgery
In elective coronary artery surgery, the continuation of P2Y12
inhibitors led to an increase in the risk of bleeding without any
clear antithrombotic benefit. The meta-analysis of the three
randomised trials CLARITY, CURE and CREDO concluded that the
risk of immediate complications after coronary artery surgery
(death, myocardial infarction and stroke) is the same whether
patients are treated preoperatively with aspirin and clopidogrel or
with aspirin alone, but that the risk of bleeding is increased by
clopidogrel [80]. Above all, the risk of major bleeding and
reoperation is increased if clopidogrel is discontinued less than
five days before CABG surgery [81].
The new P2Y12 inhibitors also carry an increased risk of
perioperative bleeding. In the randomised TRITON-TIMI-38 trial, inwhich patients with acute coronary syndrome were randomised to
treatment with aspirin and either clopidogrel or prasugrel,
3646 patients underwent coronary artery surgery. Patients treated
with prasugrel had more major bleeding, platelet transfusions and
surgical re-explorations compared to clopidogrel, and a lower rate
of death [82]. Similarly, continuation of ticagrelor before coronary
artery surgery increases the incidence of major bleeding compli-
cations [28].
The usefulness of platelet functional tests to adjust the
discontinuation duration of P2Y12 inhibitor discontinuation before
coronary artery surgery has been discussed above. Recent data
suggest that a platelet functional assessment test could be used to
reduce discontinuation time of P2Y12 inhibitors in semi-urgent
CABG surgery. Studies showing the benefit of platelet function
evaluation were performed with the Multiplate1 and TEG1
Platelet Mapping. These tests could be used for their negative
predictive value regarding bleeding.
Proposals
 A multidisciplinary approach is proposed to choose the
best management strategy for antiplatelet agents before
coronary artery surgery, according to the patient’s risk of
bleeding and thrombosis (strong agreement).
 It is proposed to continue aspirin throughout the
perioperative period.
 In patients treated with DAPT, discontinuation of the
P2Y12 inhibitor is proposed, with a last intake five days
before surgery for clopidogrel and ticagrelor, and seven
days for prasugrel (strong agreement).
 Emerging evidence suggests that urgent surgery could
be performed after a shorter duration of ticagrelor
discontinuation, with a last intake three to five days
before surgery. However, patients with no recovery of
platelet function dependent on ADP after ticagrelor
discontinuation are exposed to a risk of major postop-
erative bleeding (strong agreement).
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